Table A3.

Symptom development or clearance.

	Hydroxychloroquine +  Azithromycin n = 152*	Hydroxychloroquine n = 152*	Placebo n = 152*
Asymptomatic day one and:
Symptomatic day seven	8 of 78 (10·3%, 4·5–19·2%)	9 of 78 (11·5%, 5·4–20·1%)	13 of 85 (15·3%, 8·4–24·7%)
Symptomatic day 14	3 of 79 (3·8%, 0·8–10·7%)	3 of 77 (3·9%, 0·8–11·0%)	4 of 84 (4·8%, 1·3–11·7%)
Symptomatic day 21	4 of 78 (5·1%, 1·4–12·6%)	2 of 77 (2·6%, 0·3–9·1%)	2 of 85 (2·4%, 0·3–8·2%)
Symptomatic day one and:
Asymptomatic day seven	56 of 70 (80·0%, 68·7–88·6%)	55 of 69 (79·7%, 68·3–88·4%)	52 of 59 (88·1%, 77·1–95·1%)
Asymptomatic day 14	66 of 69 (95·7%, 87·8–99·1%)	64 of 69 (92·8%, 83·9–97·6%)	58 of 60 (96·7%, 88·5–99·6%)
Asymptomatic day 21	67 of 69 (97·1%, 89·9–99·6%)	68 of 69 (98·6%, 92·2–100·0%)	56 of 60 (93·3%, 83·8–98·2%)